1035 patients were entered into a multinational COVID-19 and Cancer Consortium (CCC19) database, and 928 met criteria for inclusion. The 30-day all-cause mortality (primary endpoint) was 13%, more than twice the mortality of global average. Factors associated with increased 30-day mortality were: increased age, male sex, smoking status, number of comorbidities, performance status (ECOG status of 2 or higher, active cancer (progressing vs remission), and receipt of azithromycin plus hydroxychloroquine. Race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality. The 30-day mortality was <10% for those with ECOG PS 0-1 vs. >30% for those with ECOG PS 2-4.  

(Open Access)

Reference (PubMed Link): Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of covid-19 on patients with cancer (ccc19): A cohort study. Lancet 2020;395:1907-1918.

Key Institution: Multi-Institutional
Keywords: Covid-19